UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): March 14, 2019 (March 12, 2019)

 

LUCKWEL PHARMACEUTICALS INC.

(Exact name of registrant as specified in its charter)

 

Nevada   333-187874   46-1660653

(State or other jurisdiction

of incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

 

303 Wyman St Suite 300, Waltham   MA 02451
(Address of principal executive offices)   (Zip Code)

 

Registrant’s telephone number, include area code +1(781)728 0007

 

 

 

100 S. Saunders Road, Suite 150, Lake Forest, IL 60045

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

[  ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
[  ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
[  ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
[  ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2).

 

Emerging growth company [  ]

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [  ]

 

 

 

     

 

 

Item 1.01 Entry into a Material Definitive Agreement

 

On March 12, 2019, Luckwel Pharmaceuticals Inc. (the “Company”) entered into an online office agreement with Regus Management Group, LLC (the “Agreement”), pursuant to which the Company leased an office space located at 303 Wyman St Suite 300, Waltham, MA 02451. The lease under the Agreement will start on March 14, 2019 on a month-to-month basis for which the Company pays a monthly fee of $500.

 

This description of the Agreement does not purport to be complete and is qualified in its entirety by reference to the form of Agreement, a copy of which is attached as Exhibit 10.1 to this Current Report on Form 8-K.

 

Item 9.01 Financial Statements and Exhibits

 

(d) Exhibits
   
10.1 Online Office Agreement dated March 12, 2019

 

     

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  LUCKWEL PHARMACEUTICALS INC.
     
Date: March 14, 2019   /s/ Kingrich Lee
  Name:  Kingrich Lee
  Title: Chief Executive Officer and Chief Financial Officer

 

     

 

 

Luckwel Pharmaceuticals (GM) (USOTC:LWEL)
Historical Stock Chart
From May 2024 to Jun 2024 Click Here for more Luckwel Pharmaceuticals (GM) Charts.
Luckwel Pharmaceuticals (GM) (USOTC:LWEL)
Historical Stock Chart
From Jun 2023 to Jun 2024 Click Here for more Luckwel Pharmaceuticals (GM) Charts.